<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ceftibuten (United States: Not available): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ceftibuten (United States: Not available): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ceftibuten (United States: Not available): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9227" href="/d/html/9227.html" rel="external">see "Ceftibuten (United States: Not available): Drug information"</a> and <a class="drug drug_patient" data-topicid="11895" href="/d/html/11895.html" rel="external">see "Ceftibuten (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1004206"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Cephalosporin (Third Generation)</span></li></ul></div>
<div class="block dop drugH1Div" id="F148046"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> All ceftibuten formulations (brand and generic) have been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: Oral: 9 mg/kg/dose once daily; maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1701ac17-544f-4206-a37e-0462fd6cd656">Chronic bronchitis, acute bacterial exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic bronchitis, acute bacterial exacerbation:</b> Children ≥12 years and Adolescents: Oral: 400 mg once daily for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute:</b>
<b> Note:</b> Ceftibuten is not included in the AAP acute otitis media guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;12 years: Oral: 9 mg/kg/dose once daily for 10 days; maximum dose: 400 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 400 mg once daily for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="002747a1-d12d-413d-9efb-492e8da1743e">Streptococcus, group A; pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; pharyngitis/tonsillitis: Note:</b> Narrow-spectrum cephalosporins (eg, cephalexin) are preferred over broad-spectrum cephalosporins such as ceftibuten (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;12 years: Oral: 9 mg/kg/dose once daily for 10 days; maximum dose: 400 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 400 mg once daily for 10 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084361"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: No adjustment needed.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 49 mL/minute: Oral: 4.5 mg/kg/dose every 24 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 5 to 29 mL/minute: Oral: 2.25 mg/kg/dose every 24 hours; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease on intermittent hemodialysis (2 or 3 times weekly): Dialyzable; 65% removed by a 2- to 4-hour hemodialysis session:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 9 mg/kg/dose (maximum dose: 400 mg/dose) after each hemodialysis session.</p></div>
<div class="block dohp drugH1Div" id="F51084362"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F148031"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9227" href="/d/html/9227.html" rel="external">see "Ceftibuten (United States: Not available): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> All ceftibuten formulations (brand and generic) have been discontinued in the US for more than 1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1701ac17-544f-4206-a37e-0462fd6cd656">Chronic bronchitis, acute bacterial exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic bronchitis, acute bacterial exacerbation:</b>
<b>Oral:</b> 400 mg once daily for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc8b3439-f4bf-4f04-abe0-2ebf4c2986c1">Otitis media, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute bacterial:</b>
<b>Oral:</b> 400 mg once daily for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40fa7bab-1326-4738-a7d8-55ba712c4813">Pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pharyngitis/tonsillitis:</b>
<b>Oral:</b> 400 mg once daily for 10 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991758"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to 49 mL/minute: 4.5 mg/kg or 200 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 5 to 29 mL/minute: 2.25 mg/kg or 100 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD) (2 or 3 times weekly): 65% removed by a 2- to 4-hour hemodialysis session; administer 400 mg or 9 mg/kg/dose (maximum: 400 mg/dose) after each hemodialysis session</p></div>
<div class="block doha drugH1Div" id="F50988905"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block adr drugH1Div" id="F147999"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Headache (≤3%), dizziness (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Nausea (≤4%), diarrhea (3% to 4%), dyspepsia (≤2%), loose stools (≤2%), abdominal pain (1% to 2%), vomiting (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hematologic &amp; oncologic: Eosinophilia (3%), decreased hemoglobin (1% to 2%), change in platelet count (increase: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hepatic: Increased serum ALT (≤1%), increased serum bilirubin (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renal: Increased blood urea nitrogen (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Agitation, anorexia, aphasia, candidiasis, constipation, dehydration, diaper rash, drowsiness, dysgeusia, dyspnea, dysuria, eructation, fatigue, fever, flatulence, hematuria, hyperkinesia, increased serum alkaline phosphatase, increased serum AST, increased serum creatinine, insomnia, irritability, jaundice, leukopenia, melena, nasal congestion, paresthesia, pruritus, pseudomembranous colitis, psychosis, rigors, serum sickness, skin rash, Stevens-Johnson syndrome, stridor, thrombocytopenia, toxic epidermal necrolysis, urticaria, vaginitis, xerostomia</p></div>
<div class="block coi drugH1Div" id="F148014"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ceftibuten, other cephalosporins, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F147996"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Penicillin allergy: Use with caution in patients with a history of penicillin allergy; if a hypersensitivity reaction occurs, discontinue therapy and institute supportive emergency measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Colitis: Use with caution in patients with a history of colitis and other gastrointestinal diseases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; modify dosage in moderate to severe impairment and in hemodialysis patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sucrose: Some formulations may contain sucrose.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878375"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">May cause diarrhea; incidence is higher in younger pediatric patients (8% in patients ≤2 years of age; 2% in patients &gt;2 years of age).</p></div>
<div class="block prod-avail drugH1Div" id="F52750675"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">All ceftibuten formulations (brand and generic) have been discontinued in the US for more than 1 year.</p></div>
<div class="block geq drugH1Div" id="F147992"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F148016"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Cedax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (20): $767.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ceftibuten Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (20): $656.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Cedax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg/5 mL (30 mL): $119.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Ceftibuten Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg/5 mL (60 mL): $553.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612387"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Administer without regard to food.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Shake suspension well before use. Administer 2 hours before or 1 hour after meals.</p></div>
<div class="block adm drugH1Div" id="F148011"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Administer without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Administer at least 2 hours before or 1 hour after meals. Shake well before use.</p></div>
<div class="block sts drugH1Div" id="F148024"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 25°C (36°F to 77°F). Reconstituted suspension is stable for 14 days when refrigerated at 2°C to 8°C (36°F to 46°F).</p></div>
<div class="block usep drugH1Div" id="F53565950"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute bacterial otitis media and pharyngitis/tonsillitis due to susceptible organisms (FDA approved in ages ≥6 months and adults); treatment of acute exacerbations of chronic bronchitis (FDA approved in ages ≥12 years and adults).</p></div>
<div class="block mst drugH1Div" id="F3195416"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cedax may be confused with Cidex</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cedax [US and multiple international markets] may be confused with Codex brand name for acetaminophen/codeine [Brazil] and <i>Saccharomyces boulardii</i> [Italy]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298997"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F148001"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F148018"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Suspension: Take 2 hours before or 1 hour after meals.</p></div>
<div class="block pri drugH1Div" id="F5952486"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins (Crider 2009). </p></div>
<div class="block mopp drugH1Div" id="F53565951"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for signs and symptoms of anaphylaxis; with prolonged therapy, monitor renal, hepatic, and hematologic function periodically; number and type of stools/day for diarrhea.</p></div>
<div class="block pha drugH1Div" id="F147995"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F148013"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid; food decreases peak concentrations, delays T<sub>max</sub>, and lowers AUC </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Distributes into middle ear fluid, bronchial secretions, and sputum; V<sub>d</sub>: Children: 0.5 L/kg; Adults: 0.21 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 65%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 75% to 90% (Owens 1997)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Children: 2 hours; Adults: 2.4 hours; CrCl 30 to 49 mL/minute: 7.1 hours; CrCl 5 to 29 mL/minute: 13.4 hours; CrCl &lt;5 mL/minute: 22.3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 2 to 2.6 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~56%); feces (39%)</p></div>
<div class="block phksp drugH1Div" id="F51220824"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is decreased and half-life is increased.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2013216">
<a name="2013216"></a>Barr WH, Lin CC, Radwanski E, et al. The pharmacokinetics of ceftibuten in humans. <i>Diagn Microbiol Infect Dis</i>. 1991;14(1):93-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/2013216/pubmed" id="2013216" target="_blank">2013216</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cedax (ceftibuten) [prescribing information]. Morristown, NJ: Pernix Therapeutics; March 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects: national birth defects prevention study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9296244">
<a name="9296244"></a>Guay DR. Ceftibuten: A new expanded-spectrum oral cephalosporin. <i>Ann Pharmacother. </i>1997;31(9):1022-1033.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/9296244/pubmed" id="9296244" target="_blank">9296244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10069359">
<a name="10069359"></a>Marshall WF and Blair JE. The cephalosporins. <i>Mayo Clin Proc</i>. 1999;74(2):187-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/10069359/pubmed" id="10069359" target="_blank">10069359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9250548">
<a name="9250548"></a>Owens RC Jr, Nightingale CH, and Nicolau DP. Ceftibuten: An overview. <i>Pharmacotherapy</i>. 1997;17(4):707-720.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/9250548/pubmed" id="9250548" target="_blank">9250548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8833562">
<a name="8833562"></a>Schatz BS, Karavokiros KT, Taeubel MA, et al. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. <i>Ann Pharmacother</i>. 1996;30(3):258-268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/8833562/pubmed" id="8833562" target="_blank">8833562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23091044">
<a name="23091044"></a>Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2012;55(10):1279-1282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/23091044/pubmed" id="23091044" target="_blank">23091044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7520858">
<a name="7520858"></a>Wiseman LR and Balfour JA. Ceftibuten: A review of its antibacterial activity pharmacokinetic properties and clinical efficacy. <i>Drugs</i>. 1994;47(5):784-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftibuten-united-states-not-available-pediatric-drug-information/abstract-text/7520858/pubmed" id="7520858" target="_blank">7520858</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13059 Version 159.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
